Immunomedics Inc (IMMU) stock price is down 29% in mid-morning trading as its lead drug, Sacituzumab Govitecan, failed to get FDA approval. Short interest is $533 million, 29.49 million shares shorted, 18.29% of its float, stock borrow cost is 30 bps.
Shorts have been actively shorting the stock since August 2018 and this news should spur on more short selling.
We are seeing additional short selling this morning, over 300k new shares shorted so far and would expect more if IMMU’s price weakness continues today.
Shorts are up $154 million in mark-to-market profits this morning, bringing year-to-date P\L into the black, up $45 million for the year.
Want deeper insight into the above analysis?
Contact: Ihor.Dusaniwsky@S3Partners.net
Managing Director Predictive Analytics, S3 Partners, LLC
For more information on S3’s reporting, data and analytics solutions, email us at sales@s3partners.net. Start your free trial of the BLACK App – the only source of real-time short interest on the Bloomberg Terminal or Thomson Reuters Eikon.
For short side data and access to our research reports go to https://shortsight.com/ .
